CR20190290A - Composición mejorada de lansoprazol y simeticona y proceso para prepararla - Google Patents
Composición mejorada de lansoprazol y simeticona y proceso para prepararlaInfo
- Publication number
- CR20190290A CR20190290A CR20190290A CR20190290A CR20190290A CR 20190290 A CR20190290 A CR 20190290A CR 20190290 A CR20190290 A CR 20190290A CR 20190290 A CR20190290 A CR 20190290A CR 20190290 A CR20190290 A CR 20190290A
- Authority
- CR
- Costa Rica
- Prior art keywords
- microgranules
- simeticone
- lansoprazole
- concentration
- preparing same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a una composición farmacéutica de administración oral, que comprende la combinación a dosis fija de Simeticona en microgránulos de alta concentración y Lansoprazol o su enantiómero (Dexlansoprazol) en microgránulos de liberación entérica y el proceso para obtener los microgránulos de alta concentración de Simeticona.The present invention relates to an orally administered pharmaceutical composition comprising a fixed-dose combination of simeticone in high-concentration microgranules and lansoprazole or the enantiomer thereof (dexlansoprazole) in enteric-release microgranules. The invention also relates to a method for obtaining the high-concentration simeticone microgranules.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2016016587A MX2016016587A (es) | 2016-12-14 | 2016-12-14 | Composicion mejorada de lansoprazol y simeticona y procesos para prepararla. |
PCT/IB2017/057904 WO2018109693A1 (es) | 2016-12-14 | 2017-12-13 | Composición mejorada de lansoprazol y simeticona y proceso para prepararla |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20190290A true CR20190290A (es) | 2019-11-18 |
Family
ID=62558163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20190290A CR20190290A (es) | 2016-12-14 | 2017-12-13 | Composición mejorada de lansoprazol y simeticona y proceso para prepararla |
Country Status (9)
Country | Link |
---|---|
AR (1) | AR110183A1 (es) |
BR (1) | BR112019011966A2 (es) |
CL (1) | CL2019001462A1 (es) |
CO (1) | CO2019006693A2 (es) |
CR (1) | CR20190290A (es) |
DO (1) | DOP2019000145A (es) |
MX (1) | MX2016016587A (es) |
PE (1) | PE20191654A1 (es) |
WO (1) | WO2018109693A1 (es) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5073384A (en) * | 1989-10-19 | 1991-12-17 | Valentine Enterprises, Inc. | Maltodextrin/defoaming composition combinate |
US6103260A (en) * | 1997-07-17 | 2000-08-15 | Mcneil-Ppc, Inc. | Simethicone/anhydrous calcium phosphate compositions |
US7101573B2 (en) * | 2001-09-28 | 2006-09-05 | Mcneil-Pcc, Inc. | Simethicone solid oral dosage form |
US20050181052A1 (en) * | 2004-02-17 | 2005-08-18 | Patel Satishkumar A. | Lansoprazole microtablets |
WO2008056200A1 (en) * | 2006-11-10 | 2008-05-15 | Ranbaxy Laboratories Limited | Oral pharmaceutical compositions of simethicone |
BR112014014278A2 (pt) * | 2011-12-14 | 2017-06-13 | Disphar Int B V | composição farmacêutica |
-
2016
- 2016-12-14 MX MX2016016587A patent/MX2016016587A/es unknown
-
2017
- 2017-11-17 AR ARP170103219A patent/AR110183A1/es unknown
- 2017-12-13 PE PE2019001165A patent/PE20191654A1/es unknown
- 2017-12-13 BR BR112019011966-3A patent/BR112019011966A2/pt unknown
- 2017-12-13 CR CR20190290A patent/CR20190290A/es unknown
- 2017-12-13 WO PCT/IB2017/057904 patent/WO2018109693A1/es active Application Filing
-
2019
- 2019-05-30 CL CL2019001462A patent/CL2019001462A1/es unknown
- 2019-06-04 DO DO2019000145A patent/DOP2019000145A/es unknown
- 2019-06-21 CO CONC2019/0006693A patent/CO2019006693A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
AR110183A1 (es) | 2019-03-06 |
BR112019011966A2 (pt) | 2019-11-05 |
WO2018109693A1 (es) | 2018-06-21 |
MX2016016587A (es) | 2018-06-13 |
DOP2019000145A (es) | 2019-08-15 |
CO2019006693A2 (es) | 2019-07-10 |
PE20191654A1 (es) | 2019-11-07 |
CL2019001462A1 (es) | 2019-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU20190005A7 (es) | Goma de mascar administrable oralmente o formulaciones acuosas que comprenden un agente farmacéutico | |
BR112017008301A2 (pt) | extratos de cannabis e métodos de sua preparação e uso | |
CL2017002817A1 (es) | Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue | |
EA201791702A1 (ru) | Терапевтические средства на основе гликанов и связанные с ними способы | |
CO2019000938A2 (es) | Moduladores nmda espiro-lactam y métodos de uso de los mismos | |
PE20151301A1 (es) | Formulaciones farmaceuticas resistentes a la manipulacion indebida | |
CL2017001026A1 (es) | Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención. | |
ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
CL2016002560A1 (es) | Forma de dosificación farmacéutica sólida oral que comprende siponimod, un agente protector de la humedad y opcionalmente un excipiente farmacéutico; procedimiento de preparación. | |
EA201190161A1 (ru) | Способ получения твердых лекарственных форм солифенацина и его фармацевтически приемлемых солей для перорального введения | |
MX2018012618A (es) | Composiciones farmaceuticas orales de mesalazina. | |
CR20150266A (es) | Formulaciones de liberación modificada para oprozomib | |
PH12019500154A1 (en) | Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof | |
CY1124893T1 (el) | Φαρμακευτικο μeιγμα μαροπιταντης | |
CL2018003682A1 (es) | Composición farmacéutica oral, que comprende un agente farmacéuticamente activo, al menos un polímero catiónico bioadhesivo y al menos dos polímeros aniónicos. | |
CL2020000601A1 (es) | Composición farmacéutica. | |
AR108233A1 (es) | Composiciones farmacéuticas orales de nicotinamida | |
CR20190290A (es) | Composición mejorada de lansoprazol y simeticona y proceso para prepararla | |
ECSP19044926A (es) | Composición mejorada de lansoprazol y simeticona y proceso para prepararla | |
UY37518A (es) | Formas de dosificación de liberación modificada gastroretentivas para oprozomib y proceso para su fabricación | |
PE20160245A1 (es) | Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido dispersable que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion | |
CY1125762T1 (el) | Νεα απο του στοματος σκευασματα βελινοστατης | |
BR112018074655A2 (pt) | formulação injetável de fosnetupitant e método de fabricação de uma formulação | |
ECSP16005208A (es) | Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación | |
UY37413A (es) | Formulaciones de liberación inmediata de oprozomib |